NTRK1 and acute myeloid leukemia: IGF1R is one of the phosphorylated receptor tyrosine kinases present in AML cases, and it has been linked to mutant RAS-positive AML, having the potential therapeutic benefits of dual suppression of IGF1R and RAS signaling [44].